参考文献/References:
[1] Turner N, Zeng XY, Osborne B,et al. Repurposing drugs to target the diabetes epidemic[J].Trends Pharmacol Sci,2016,37(5):379-389. DOI:10.1016/j.tips.2016.01.007.
[2] Chowdhury MK,Turner N,Bentley NL,et al.Niclosamide reduces giucagon sensitivity via hepatic PKA inhibition in obese mice: implications for glucose metabolism improvements in type 2 diabetes[J].Sci Rep,2017,7:40159. DOI:10.1038/srep40159.
[3] Tzoulaki I,Ebbels TM,Valdes A,et al.Design and analysis of metabolomics studies in epidemiologic research:a primer on -omic technologies[J].Am J Epidemiol,2014,180(2):129-139.DOI:10.1093/aje/kwu143.
[4] Nicholson JK,Holmes E,Kinross JM,et al. Metabolic phenotyping in clinical and surgical environments[J].Nature,2012,491(7424):384-392.DOI:10.1038/nature11708.
[5] Verma M,Khoury MJ,Ioannidis JP.Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling[J].Cancer Epidemiol Biomarkers Prev,2013,22(2):189-200.DOI:10.1158/1055-9965.EPI-12-1263.
[6] Emwas AH.The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research[J].Methods Mol Biol,2015,1277:161-193. DOI:10.1007/978-1-4939-2377-9_13.
[7] Pourmodheji H, Ghafar-Zadeh E, Magierowski S. A multidisciplinary approach to high throughput nuclear magnetic resonance spectroscopy[J].Sensors(Basel),2016,16(6):pii: E850.DOI:10.3390/s16060850.
[8] Patti GJ,Yanes O,Siuzdak G.Innovation: metabolomics: the apogee of the omics trilogy[J].Nat Rev Mol Cell Biol,2012,13(4):263-269. DOI:10.1038/nrm3314.
[9] Mook-Kanamori DO,Selim MM,Takiddin AH,et al.1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control[J].J Clin Endocrinol Metab,2014,99(3):E479-E483.DOI:10.1210/jc.2013-3596.
[10] Perry RJ,Peng L,Barry NA,et al.Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome[J].Nature,2016,534(7606):213-217. DOI:10.1038/nature18309.
[11] Li L,Wang C,Yang H,et al.Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients[J].Mol Biosyst,2017,13(11):2392-2400. DOI:10.1039/c7mb00167c.
[12] Zhao L,Ni Y,Ma X,et al.A panel of free fatty acid ratios to predict the development of metabolic abnormalities in healthy obese individuals[J].Sci Rep,2016,6:28418.DOI:10.1038/srep28418.
[13] Mack LR, Tomich PG. Gestational diabetes: diagnosis, classification, and clinical care[J]. Obstet Gynecol Clin North Am, 2017,44(2):207-217.DOI:10.1016/j.ogc.2017.02.002.
[14] Law KP, Zhang H. The pathogenesis and pathophysiology of gestational diabetes mellitus: deductions from a three-part longitudinal metabolomics study in China[J].Clin Chim Acta,2017,468:60-70. DOI:10.1016/j.cca.2017.02.008.
[15] Zheng H,Lin Q,Wang D,et al.NMR-based metabolomics reveals brain region-specific metabolic alterations in streptozotocin-induced diabetic rats with cognitive dysfunction[J].Metab Brain Dis,2017,32(2):585-593. DOI:10.1007/s11011-016-9949-0.
[16] Sun T,Rong Y,Hu X,et al.Plasma alkylresorcinol metabolite, a biomarker of whole-grain wheat and rye intake, and risk of type 2 diabetes and impaired glucose regulation in a Chinese population[J].Diabetes Care,2018,41(3):440-445.DOI:10.2337/dc17-1570.
[17] Tanaka S,Tanaka S,Iimuro S,et al.Cohort profile: the Japan diabetes complications study: a long-term follow-up of a randomised lifestyle intervention study of type 2 diabetes[J].Int J Epidemiol,2014,43(4):1054-1062.DOI:10.1093/ije/dyt057.
[18] Zhao J, Zhu Y, Hyun N,et al. Novel metabolic markers for the risk of diabetes development in American Indians[J].Diabetes Care,2015,38(2):220-227. DOI:10.2337/dc14-2033.
[19] Floegel A,Stefan N,Yu Z,et al.Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach[J].Diabetes,2013,62(2):639-648.DOI:10.2337/db12-0495.
[20] Ni Y,Zhao L,Yu H,et al.Circulating unsaturated fatty acids delineate the metabolic status of obese individuals[J].EBioMedicine,2015,2(10):1513-1522.DOI:10.1016/j.ebiom.2015.09.004.
[21] Chen T, Ni Y, Ma X, et al. Branched-chain and aromatic amino acid profiles and diabetes risk in chinese populations[J]. Sci Rep, 2016, 6:20594. DOI: 10.1038/srep20594.
[22] Chen T,Zheng X,Ma X,et al.Tryptophan predicts the risk for future type 2 diabetes[J].PLoS One,2016,11(9):e0162192.DOI:10.1371/journal.pone.0162192.
[23] Cobb J,Eckhart A,Motsinger-Reif A,et al.α-hydroxybutyric acid is a selective metabolite biomarker of impaired glucose tolerance[J].Diabetes Care,2016,39(6):988-995.DOI:10.2337/dc15-2752.
[24] Pena MJ,de Zeeuw D,Andress D,et al.The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy[J].Diabetes Obes Metab,2017,19(5):749-753.DOI:10.1111/dom.12864.
[25] Tao Y,Chen X,Cai H,et al.Untargeted serum metabolomics reveals Fu-Zhu-Jiang-Tang tablet and its optimal combination improve an impaired glucose and lipid metabolism in type Ⅱ diabetic rats[J].J Chromatogr B Analyt Technol Biomed Life Sci,2017,1040:222-232.DOI:10.1016/j.jchromb.2016.11.012.
[26] Xu T,Brandmaier S,Messias AC,et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes[J].Diabetes Care,2015,38(10):1858-1867.DOI:10.2337/dc15-0658.
[27] Zhao T,Zhang H,Zhang X,et al.Metabolomic and lipidomic study of the protective effect of Chaihuang-Yishen formula on rats with diabetic nephropathy[J].J Ethnopharmacol,2015,166:31-41.DOI:10.1016/j.jep.2015.02.019.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(05):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]